Tuesday, September 27, 2005

Sirna gets patent in RNAi therapeutics

Sirna Therapeutics, Inc., a clinical-stage RNAi therapeutics
company, announced Sept. 27 that the United Kingdom Patent Office has issued a broad patent covering RNA interference (RNAi) mediated inhibition of gene expression using short-interfering ribonucleic acids (siRNA). The patent claims, which are not limited to a specific siRNA sequence or structure, broadly cover any siRNA molecule which targets conserved sequences within a
virus or a gene. This patent is important because it enables increased therapeutic potential of RNAi technology.


Post a Comment

<< Home